The Los Angeles-based AIDS Healthcare Foundation circulated petitions to get an initiative on the Nov. 8 ballot that would cap what state agencies pay for drugs at the price negotiated by the VA. And polls suggest the proposal, Proposition 61, has a strong chance of winning.
Two top lawmakers on Thursday demanded information from a drug company that has raised prices on a leukemia drug, calling increases of tens of thousands of dollars a sign the company puts profits before patients.
In many countries, indiscriminate antibiotic use in humans, agriculture and animals used for food production has led to the rise of bacteria that are resistant to all commercially available antibiotics. Many are now asking: “Have we returned to a pre-antibiotic era?”
Omnicare, the largest nursing home pharmacy in the country based on the number of beds served, will pay $28.1 million to settle allegations that it requested and accepted kickbacks from Abbott Laboratories to promote the drugmaker's epilepsy drug Depakote.
Industry experts say the Obama administration's decision to lift a ban on importing Cuban pharmaceuticals and collaborating with the nation's researchers could bring the nation's cheaper, reputable medicines to the U.S. The move could give American researchers the chance to study Cuba's care...
There are many reasons for the nation's rising prescription drug spending, which increased 6.3% from August 2015 to August 2016. But you wouldn't think one of them would be that the federal government is actively encouraging drug companies to slap higher price tags on old, cheap products.
Tech executive Kevin MacDonald says his Kit Check system allows hospital pharmacies to cut the time it takes to fill kits and trays by 70% to 90% while also virtually eliminating errors.
Doctors Without Borders is refusing 1 million free pneumonia vaccines from Pfizer because it objects to restrictions that often come with donated vaccines. The not-for-profit is also concerned about how Pfizer and other drugmakers use donations to justify charging high prices to other buyers.
America's crisis of rising drug prices has hit hospitals even harder than it has consumers, according to a recent study from America's biggest hospital lobbies.
Mylan, the embattled maker of the EpiPen, has agreed to pay the U.S. Justice Department $465 million to resolve questions surrounding the potential misclassification of the device as a generic under the Medicaid Drug Rebate Program.
Even the federal government is apparently paying too much for EpiPens, along with angry patients and insurers.
Modern Healthcare Midwest Bureau Chief Bob Herman recently interviewed Mark Merritt, CEO of the Pharmaceutical Care Management Association, the PBM trade group, to get his take on the issues facing the industry.